|
ATMIN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.13039996544273E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.86539999949653E-07 |
| Normal-vs-Stage2 |
1.487700E-02 |
| Normal-vs-Stage3 |
2.44140000438264E-08 |
| Normal-vs-Stage4 |
2.45600000337021E-08 |
| Stage1-vs-Stage2 |
1.109650E-01 |
| Stage1-vs-Stage3 |
7.662200E-02 |
| Stage1-vs-Stage4 |
8.297000E-03 |
| Stage2-vs-Stage3 |
8.582700E-03 |
| Stage2-vs-Stage4 |
1.503910E-03 |
| Stage3-vs-Stage4 |
3.667600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.01260000279413E-08 |
| Normal-vs-AfricanAmerican |
8.996000E-04 |
| Normal-vs-Asian |
6.26769999999555E-05 |
| Caucasian-vs-AfricanAmerican |
9.046600E-01 |
| Caucasian-vs-Asian |
7.007400E-01 |
| AfricanAmerican-vs-Asian |
7.068200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.24550000002444E-06 |
| Normal-vs-Female |
9.22400000824553E-09 |
| Male-vs-Female |
6.557800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.5445999999606E-06 |
| Normal-vs-Age(41-60Yrs) |
8.28070000347125E-08 |
| Normal-vs-Age(61-80Yrs) |
3.85650000045423E-07 |
| Normal-vs-Age(81-100Yrs) |
5.858200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.727600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.952000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.274000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.289200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.732400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.584600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.324400E-02 |
| Classical-VS-Follicular |
4.786600E-01 |
| Classical-VS-Other |
1.652620E-01 |
| Classical-VS-Normal |
5.04289999980756E-07 |
| Tall-VS-Follicular |
3.044400E-01 |
| Tall-VS-Other |
4.467800E-01 |
| Tall-VS-Normal |
2.43470000005352E-06 |
| Follicular-VS-Other |
2.803200E-01 |
| Follicular-VS-Normal |
1.80743000000039E-05 |
| Other-VS-Normal |
5.763400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87459999967388E-07 |
| Normal-vs-N1 |
7.45899999543553E-08 |
| N0-vs-N1 |
3.488300E-02 |
|
|
